Evogene Stock Price, News & Analysis

Evogene (NASDAQ: EVGN) subsidiary Biomica granted Shanghai Lishan Biopharmaceuticals an exclusive worldwide license to BMC128 (LS-LBP-002), a live four-strain microbiome-based therapeutic showing early Phase 1 clinical promise in renal cell carcinoma and non-small cell lung cancer.

BMC128 displayed an excellent safety profile and early signs of efficacy, including disease stabilization in patients with prior progression. Under the deal, Lishan Biotech will lead global development, manufacturing, and commercialization; Biomica is eligible for development milestones and future royalties. Lishan plans Phase 2 studies and regulatory filings in China and the United States.

Evogene (NASDAQ: EVGN) and Unravel Biosciences announced a collaboration on January 7, 2026 to discover and optimize a first-in-class small-molecule therapy aimed at restoring myelin and reversing neurological damage in demyelinating disorders including multiple sclerosis.

The program combines Evogene's ChemPass AI generative chemistry platform with Unravel's BioNAV predictive biology and Living Molecular Twins patient-derived data to design brain-penetrant inhibitors against a novel demyelination target discovered by Unravel. Work will use in vitro, in vivo, and in silico outcome simulation to advance lead candidates toward potential clinical development.

Evogene (Nasdaq: EVGN) appointed Dr. Olga Nissan as Vice President of Business Development, effective January 1, 2026. Dr. Nissan brings more than 15 years of experience across biotechnology, pharmaceutical and AI-enabled drug discovery and holds a PhD plus postdoctoral research in biochemistry and proteomics from the Weizmann Institute of Science.

Her prior roles include CEO and Co‑Founder of Protica Bio and senior R&D and management positions at EcoPhage, BiomX and Teva. Management says she will help scale Evogene's small‑molecule discovery and optimization powered by the ChemPass AI platform and expand industry collaborations.

Casterra and Fantini announced a strategic collaboration on November 11, 2025 to develop integrated, mechanized solutions for large-scale commercial castor farming.

The partnership pairs Casterra's proprietary high-yield castor varieties with Fantini's precision harvesting and threshing machinery to enable scalable production of castor oil feedstock for biofuels and bio-based products. The release cites a global castor oil market valued at USD 2.4 billion, projected to reach USD 3.09 billion by 2030 at a 5.20% CAGR. Fantini estimates its solutions can cut carbon footprint by about two-thirds versus widely used alternatives.

Evogene (NASDAQ: EVGN) will release its third quarter 2025 financial results on Thursday, November 20, 2025. Company management will host a Zoom conference call the same day at 9:00 AM ET (4:00 PM Israel time) to discuss the results. Investors must register in advance to attend: https://www.veidan-conferencing.com/evogene. The full conference will be available on the company website a few days after the call.

Evogene (NASDAQ: EVGN) announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025. CEO Ofer Haviv will present on September 10, 2025, at 1:00 PM ET, focusing on the company's strategic shift towards maximizing value from its ChemPass AI technology for small molecule discovery in pharmaceutical and agricultural applications.

The presentation will showcase the company's proprietary generative AI tech-engine capabilities. One-on-one meetings with management will be available for interested investors and companies attending the conference.

Evogene (NASDAQ: EVGN) reported Q2 2025 financial results, highlighting its strategic transformation focused on ChemPass AI, its platform for AI-driven small molecule discovery. The company reported H1 2025 revenues of $3.2 million, up from $2.3 million in H1 2024, while reducing operating expenses to $7.7 million from $11.1 million year-over-year.

Key developments include the sale of Lavie Bio's assets and MicroBoost AI for Ag to ICL for $18.71 million, completion of a major restructuring with a 30% workforce reduction at Evogene and 40% at AgPlenus, and raising $4.4 million through ATM facility. The company's cash position stood at $11.7 million as of June 30, 2025, with an 18-month operational runway post-ICL transaction.

Evogene (NASDAQ: EVGN) has announced a strategic collaboration with Professor Ehud Gazit from Tel Aviv University to develop novel therapeutics for metabolic diseases. The partnership, facilitated by Ramot, combines Evogene's ChemPass AI platform with Professor Gazit's expertise in molecular self-assembly to target diseases caused by metabolite accumulation.

The collaboration aims to develop small molecules that can inhibit pathological self-assembly processes in diseases such as Tyrosinemia, Gout, and Maple Syrup Urine Disease (MSUD). The project will leverage ChemPass AI's advanced algorithms to understand therapeutic modes of action and design novel molecules for treatment.

Evogene (NASDAQ: EVGN), a computational biology company focused on life-science product discovery and development, has scheduled its Q2 2025 financial results release for Tuesday, August 19, 2025. The company will host a conference call to discuss the results at 9:00 AM ET (4:00 PM Israel time).

Interested participants must register in advance through the company's dedicated conference link. A recording of the conference will be made available on Evogene's website following the event.